Dr. Saikrishna Gadde
Claim this profileUniversity of Tennessee - Knoxville
Studies Bladder Cancer
Studies Skin Cancer
9 reported clinical trials
23 drugs studied
Area of expertise
1Bladder Cancer
Stage IV
Stage III
HER2 positive
2Skin Cancer
Stage IV
Stage III
HER2 positive
Affiliated Hospitals
Clinical Trials Saikrishna Gadde is currently running
Disitamab Vedotin + Pembrolizumab vs Chemotherapy
for Bladder Cancer
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.
Recruiting2 awards Phase 3
Immunotherapy + Targeted Therapy
for Genitourinary Cancers
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.
Recruiting1 award Phase 221 criteria
More about Saikrishna Gadde
Clinical Trial Related1 year of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Saikrishna Gadde has experience with
- Carboplatin
- Cisplatin
- Nivolumab
- Cabozantinib S-malate
- Ipilimumab
- Avelumab
Breakdown of trials Saikrishna Gadde has run
Bladder Cancer
Skin Cancer
Transitional Cell Carcinoma
Uterine Tumors
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Saikrishna Gadde specialize in?
Is Saikrishna Gadde currently recruiting for clinical trials?
Are there any treatments that Saikrishna Gadde has studied deeply?
What is the best way to schedule an appointment with Saikrishna Gadde?
What is the office address of Saikrishna Gadde?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.